• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by SAB Biotherapeutics Inc.

    5/15/26 4:00:02 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SABS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    SAB BIOTHERAPEUTICS, INC.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)




    78397T202

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    78397T202


    1Names of Reporting Persons

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,431,743.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,431,743.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,431,743.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.4 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP Number(s):
    78397T202


    1Names of Reporting Persons

    Joseph Edelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,431,743.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,431,743.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,431,743.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    78397T202


    1Names of Reporting Persons

    Perceptive Life Sciences Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,431,743.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,431,743.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,431,743.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.4 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SAB BIOTHERAPEUTICS, INC.
    (b)Address of issuer's principal executive offices:

    777 W 41st St, Suite 401, Miami Beach, Florida 33140
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, $0.0001 par value per share (the "Common Stock") of SAB BIOTHERAPEUTICS, INC. (the "Issuer") are: Perceptive Advisors LLC ("Perceptive Advisors") Joseph Edelman ("Mr. Edelman") Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor New York, NY 10003
    (c)Citizenship:

    Perceptive Advisors is a Delaware limited liability company Mr. Edelman is a United States citizen The Master Fund is a Cayman Islands corporation
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    78397T202
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 76,464,094 shares of Common Stock outstanding, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026. The Master Fund directly holds 6,431,743 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own the securities directly held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities directly held by the Master Fund.
    (b)Percent of class:

    Perceptive Advisors: 8.4% Mr. Edelman: 8.4% Master Fund: 8.4%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (ii) Shared power to vote or to direct the vote:

    Perceptive Advisors: 6,431,743 Mr. Edelman: 6,431,743 Master Fund: 6,431,743

     (iii) Sole power to dispose or to direct the disposition of:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Perceptive Advisors: 6,431,743 Mr. Edelman: 6,431,743 Master Fund: 6,431,743

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2026
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman
    Date:05/15/2026
     
    Perceptive Life Sciences Master Fund, Ltd.
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2026
    Get the next $SABS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SABS

    DatePrice TargetRatingAnalyst
    5/22/2026$11.00Buy
    Citigroup
    5/20/2026$11.00Buy
    Jefferies
    4/3/2026$13.00Buy
    Rodman & Renshaw
    4/2/2026$13.00Buy
    Rodman & Renshaw
    12/19/2025$15.00Buy
    Guggenheim
    9/17/2025$7.00Outperform
    Leerink Partners
    5/14/2025$10.00Buy
    H.C. Wainwright
    10/9/2024$11.00Buy
    Craig Hallum
    More analyst ratings

    $SABS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

    MIAMI, May 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it will present data at two congresses in June. SAB BIO will present an oral presentation at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) being held June 5-8, 2026, in New Orleans, LA. The Company will also present a poster presentation at the Federation of Clinical Immunology Societies (FOCIS) 2026 Annual Meeting being held June 9-12, 2026, in San Francisco, CA. Data to be presented will highlight SAB

    5/29/26 8:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

    Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities Conference call today at 8:30 AM ET MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human an

    5/12/26 7:30:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

    MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates. To access the live conference call, participants may register here. Conference Details: Conference Date: Tuesday, May 12, 2026Conference Time: 8:30 AM ETConference Dial-in: 1-877-704-4453International Dial-in: 1-201

    5/5/26 8:30:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on SAB BIO with a new price target

    Citigroup initiated coverage of SAB BIO with a rating of Buy and set a new price target of $11.00

    5/22/26 8:49:34 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies initiated coverage on SAB BIO with a new price target

    Jefferies initiated coverage of SAB BIO with a rating of Buy and set a new price target of $11.00

    5/20/26 8:07:18 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on SAB BIO with a new price target

    Rodman & Renshaw initiated coverage of SAB BIO with a rating of Buy and set a new price target of $13.00

    4/3/26 10:44:59 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SAB Biotherapeutics Inc.

    SCHEDULE 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)

    5/15/26 4:00:02 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by SAB Biotherapeutics Inc.

    SCHEDULE 13G - SAB Biotherapeutics, Inc. (0001833214) (Subject)

    5/15/26 11:17:49 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by SAB Biotherapeutics Inc.

    SCHEDULE 13G - SAB Biotherapeutics, Inc. (0001833214) (Subject)

    5/15/26 6:28:34 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kropotova Alexandra

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    3/25/26 4:35:02 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by PRESIDENT Sullivan Eddie Joe

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    2/5/26 4:55:03 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by CEO Reich Samuel J

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    2/5/26 4:50:05 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sullivan Eddie Joe bought $1,531 worth of shares (1,740 units at $0.88), increasing direct ownership by 0.03% to 5,232,304 units (SEC Form 4)

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    12/8/23 8:00:05 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    King Michael bought $4,500 worth of shares (5,000 units at $0.90) (SEC Form 4)

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    11/30/23 5:00:07 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Reich Samuel J bought $9,842 worth of shares (11,000 units at $0.89), increasing direct ownership by 5% to 219,001 units (SEC Form 4)

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    11/30/23 8:00:04 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    Leadership Updates

    Live Leadership Updates

    View All

    SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

    David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D., as an independent director, both effective immediately. "We are excited to welcome Dr. David Zaccardelli and Dr. Rita Jain to our Board of Directors. I, along with the rest of our Board, am confi

    1/7/26 8:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Reports Full Year 2024 Operating and Financial Results

    MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the fourth quarter of 2024 in addition to its full year financial results for the fiscal year ended December 31, 2024, and reported on recent accomplishments and anticipated milestones. Samuel J. Reich, Chairman and CEO of SAB BIO stated, "Our recent announcement of positive topline data for SAB-142, further strengthens our belief that SAB-142 has the pote

    3/31/25 7:32:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

    FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2024, and provided a company update. "We've had a strong quarter as we drive closer to our upcoming SAB-142 milestones. We continue to see an urgent need for transformative therapies in this spa

    8/8/24 5:51:04 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    Financials

    Live finance-specific insights

    View All

    SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

    MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates. To access the live conference call, participants may register here. Conference Details: Conference Date: Tuesday, May 12, 2026Conference Time: 8:30 AM ETConference Dial-in: 1-877-704-4453International Dial-in: 1-201

    5/5/26 8:30:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

    SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support that SAB-142 is well-positioned for re-dosing in outpatient setting for type 1 diabetesResults will be presented in an R&D webinar event today at 8:00 am ET; registration details below MIAMI, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today an

    1/28/25 7:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

    MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO's management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division chief of the Pediatric Endocrinology Division at the University of Florida and S

    1/23/25 7:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SAB Biotherapeutics Inc. (Amendment)

    SC 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)

    2/14/24 4:05:33 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by SAB Biotherapeutics Inc.

    SC 13G - SAB Biotherapeutics, Inc. (0001833214) (Subject)

    2/14/24 7:02:03 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by SAB Biotherapeutics Inc. (Amendment)

    SC 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)

    2/14/24 6:28:12 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care